Showing results (2261-2270 of 2,455) with videos related to

Sort By:
Pageof 246
NPJ Parkinson'S Disease|July 11, 2025
Parkinson's paradox: alpha-synuclein's selective strike on SNc dopamine neurons over VTAL Phan, D Miller, A Gopinath, et al.
Prostaglandins & Other Lipid Mediators|August 9, 2011
Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancerBrigette L Tippin, A Joan Levine, Alicia M Materi, et al.
Gastrointestinal Endoscopy|October 1, 1996
When to discharge patients with bleeding peptic ulcers: a prospective study of residual risk of rebleedingP I Hsu, K H Lai, X Z Lin, et al.
JHLT Open|June 13, 2025
One-year lung transplantation outcomes for engineered stone countertop workers with silicosis at a single center in Southern California, 2019 to 2023Reice Robinson, Jeremy T Hua, Bryanna Lee, et al.
Gastroenterology|December 31, 2003
Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinaseBenjamin Chun-Yu Wong, Xiao Hua Jiang, Marie C m Lin, et al.
JAMA|October 20, 1998
Center-specific graft and patient survival rates: 1997 United Network for Organ Sharing (UNOS) reportH M Lin, H M Kauffman, M A McBride, et al.
Carcinogenesis|March 19, 2014
Modulation of aryl hydrocarbon receptor (AHR)-dependent signaling by peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in keratinocytesMichael G Borland, Prasad Krishnan, Christina Lee, et al.
JAMA Dermatology|October 18, 2023
Extensive Perineural Invasion vs Nerve Caliber to Assess Cutaneous Squamous Cell Carcinoma PrognosisPaul R Massey, David M Wang, Fadi Murad, et al.
Hepatology (Baltimore, Md.)|August 3, 2011
Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signalingJin-fang Zhang, Ming-liang He, Wei-ming Fu, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Pageof 246